Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027807 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Women With Stage IV Breast Cancer
A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00027807 is a Phase 1 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 6 participants.
The verdict
NCT00027807, a Phase 1 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining different biological therapies in treating women who have stage IV breast cancer.
Interventions
- BIOLOGICAL Aldesleukin
- BIOLOGICAL Sargramostim
- BIOLOGICAL therapeutic autologous lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2001-10 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027807
The ClinicalTrials.gov registry entry for NCT00027807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aldesleukin is the first listed.
NCT00027807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027807 about?
NCT00027807 is a clinical study titled "Biological Therapy in Treating Women With Stage IV Breast Cancer". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining different biological therapies in trea...
What is the current status of trial NCT00027807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2001-10. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00027807?
The interventions under investigation include: Aldesleukin (BIOLOGICAL), Sargramostim (BIOLOGICAL), therapeutic autologous lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00027807?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.